DSM - asas.or.jp

1 20 1 1 6 1 1 1-4 CQ1-1 1 CQ1-2 CQ1-3 CQ1-4 CQ CQ 1 CQ 21 1 DSM 1 1 1 FGAs SGAs 2 SGAs 3 4 5 1 22 1 Lehman AF, Lieberman JA, Dixon LB, et al Practice guideline for the treatment of patients with schizophrenia, second edition.

2 Am J Psychiatry 161 2 Suppl 1-56, 2004 2 Salimi K, Jarskog LF, Lieberman JA Antipsychotic drugs for first-episode schizophrenia a comparative review. CNS Drugs 23 837-855, 2009 3 Buchanan RW, Kreyenbuhl J, Kelly DL, et al The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36 71-93, 2010 4 Hasan A, Falkai P, Wobrock T, et al World Federation of Societies of Biological Psychiatry WFSBP Guidelines for Biological Treatment of Schizophrenia, part 1 update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13 318-378, 2012 23 CQ1-1 second generation antipsychotics SGAs first generation antipsychotics FGAs SGAs SGAs A SGAs SGAs A SGAs randomized controlled trial RCT SGAs D SGAs 2A SGAs 2D N=8 n=528 1 SGAs , , , , Amisulpride, Zyprasidone FGAs N=13 n=2.

3 509 2 13 SGAs FGAs 24 96 SGAs FGAs SGAs SGAs SGAs SGA SGA RCT SGAs RCT ziprasidone 52 RCT3 24 ziprasidone 52 RCT4 HbA1c HDL 12 2 5, 6 42 LDL 8 7 Positive and Negative Syndrome Scale PANSS 23 26 26 30 28 28 32 25 29 2 RCT8.

4 9 2 10 29 24 4 11 4 SGAs 52 RCT12 SGAs RCT SGAs RCT SGAs FGAs SGAs SGAs 13 14 QT 25 1 Leucht S, Tardy M, Komossa K, et al Antipsychotic drugs versus placebo for relapse prevention in schizophrenia a systematic review and meta-analysis.

5 Lancet 379 2063-2071, 2012 2 Zhang JP, Gallego JA, Robinson DG, et al Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis a systematic review and meta-analysis. Int J Neuropsychopharmacol 16 1205-1218, 2013 3 Crespo-Facorro B, de la Foz VO, Mata I, et al Treatment of first-episode non-affective psychosis a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology Berl 231 357-366, 2014 4 Zhang Y, Dai G Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol 27 605-614, 2012 5 Yoshimura R, Hori H, Ikenouchi-Sugita A, et al Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.

6 Hum Psychopharmacol 27 33-38, 2012 6 Takahashi H, Oshimo T, Ishigooka J Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia an open-label trial. Clin Neuropharmacol 32 149-150, 2009 7 Yoshimura R, Ueda N, Hori H, et al Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 11 256-261, 2010 8 Robinson DG, Woerner MG, Napolitano B, et al Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia 4-month outcomes. Am J Psychiatry 163 2096-2102, 2006 9 Crespo-Facorro B, P rez-Iglesias R, Ramirez-Bonilla M, et al A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

7 J Clin Psychiatry 67 1511-1521, 2006 10 Yoshimura R, Ueda N, Shinkai K, et al Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18 107-111, 2003 11 Hori H, Ueda N, Yoshimura R, et al Olanzapine orally disintegrating tablets Zyprexa Zydis rapidly improve excitement components in the acute phase of first-episode schizophrenic patients an open-label prospective study. World J Biol 26 Psychiatry 10 741-745, 2009 12 Kahn RS, Fleischhacker WW, Boter H, et al Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder an open randomised clinical trial. Lancet 371 1085-1097, 2008 13 Moritz S, Favrod J, Andreou C, et al Beyond the usual suspects positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis.

8 Schizophr Bull 39 917-922, 2013 14 Psychosis and schizophrenia in adults treatment and management. NICE clinical guideline 178, 2014 27 CQ1-2 C RCT D D C A D 506mg/ C B 2mg/ 4mg/ 2mg/ RCT 1 C 2mg/ 8mg/ 2mg/ RCT 1 C 2C 2C CQ 1-4 C /

9 RCT RCT RCT 6 4 12 28 3 5-7 1 n=19 8 1 RCT 2 9, 10 1 HbA1c 9 RCT RCT 11 4 16 6 11-16 1 3 5 17-21 RCT Clinical Antipsychotic Trials of Intervention Effectiveness CATIE 22 RCT 1 RCT 1 9 RCT RCT 5 6 12 2 6, 7 1 3 10, 18.

10 19 506mg/ CATIE 22 53 2mg/ 4mg/ 8 RCT 1 n=49 23 2mg/ RCT 10 4 16 6 12-16,24 1 3 4 18,20,21,25 CATIE 22 6 RCT n=183 24 6mg/ 6mg/ 1 n=74 26 1 4mg/ 5 8mg/ 2mg/ 2 4mg/ 29 8 n=96 27 2mg/ 4mg/ FGAs 2mg/ 8mg/ 6 RCT 1 n=40 28 2 RCT 9 6 12 4 11,12,14,15 1 3 5 17,19-21,25 3 17,19.